IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Guo et al.

Examiner:

Application No.: 09/933,780

AND USES THEREOF

Art Unit:

MEMBRANE PENETRATING PEPTIDES

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

02

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents Washington, D.C. 20231

Sir:

X

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

Filed: August 21, 2001

FEB 2 6 2002

7	(b)	This	Information Disclosure Statement is filed after the period set forth in
-	` ,	1.97	(b), but is believed to be filed before the mailing date of a final action under s
			notice of allowance under §1.311, whichever occurs first.
	П	(1)	The undersigned attorney certifies that each item of information contained in this
		` ,	Information Disclosure Statement was cited in a communication from a foreign
			patent office in a counterpart foreign application not more than three months prior
			to the filing of this statement;
		(2)	The undersigned attorney certifies that no item of information contained in this
			Information Disclosure Statement was cited in a communication from a foreign
			patent office in a counterpart foreign application or, to the knowledge of the
			undersigned attorney after making reasonable inquiry, was known to any
			individual designated in §1.56(c) more than three months prior to the filing of this
			statement; or
		(3)	This Information Disclosure Statement is accompanied by a transmittal letter in
			which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is
			authorized.
			Respectfully submitted,
			the fame
			T. Helen Payne, Reg. No. 36,889
			Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-5789
Telefax (908) 231-2626
Aventis Docket No. HMR2053 US NP1

Please type a plus sign (+) inside this box ->
--

PTO/SB/08A (10-96) Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Compl t if Kn wn

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of Sheet

RECEI ED

MAR 10 6 2002

TEN 1600/2900 **Application Number** 09/933,780 Filing Date 08-21-2001 First Named Inventor **GUO** 1646 Group Art Unit **Examiner Name** Attorney Docket Number USHMR2053

				U.S. PATENT DOCU	JMENTS	
Examiner Initials	Cite No.1	Number	iment d Code² known)	Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
-	AA	5,674,980		Frankel et al.		
	AB	5,747,641		Frankel et al.		
	AC	5,804,604		Frankel et al.		
	AD	5,929,042		Troy et al.		
	ΑE	6,217,912		Park et al.		
	AF	6,248,558		Lin et al.		
	AG	6,258,774	1	Stein et al.		
	АН	5,877,282		Nadler et al.		
	AI	5,766,903		Sarnow et al.		
	AJ	6,316,003		Frankel et al.		
	AK	5,670,617		Frankel et al.		
	AL	5,652,122		Frankel et al.		
			ļ			
<u> </u>			<u> </u>			

				FORE	IGN PATENT DOCUMENT	rs		
Examiner Initials*			Foreign Patent Do	Coument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	AM	wo	WO 00/32236			06-08-2000		
	AN	wo	WO 00/32237			06-08-2000		
	AO	WO	WO 99/07728			02-18-1999		
								₩
								+
								

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

			ſ							
, •	• •									
			(+) inside this			Patent and Tradema	roved for use through 1 ark Office: U.S. DEPAR	TMENT OF COMM	-0031 ERCE	\dashv
011					o persons are required to re	espond to a collection of information unless it contains a valid OMB control number Complete if Known				
			orm 1449B/PT(COLOCUEE	Application Number				
					SCLOSURE	Filing Date	08-21-2001	Dra		Į
	STA	TE	MENT	3Y /	APPLICANT	First Named Inventor	GUO	UP (C)	44	-
OPE						Group Art Unit	1646		<u>, </u>	
10, 6		(u	se as many s	heets a	as necessary)	Examiner Name	ļ	MADA		ļ ~ •
/ <u>P</u>	Sheet		1	of	2	Attorney Docket Number	USHMR2053	nt 0 6	200	Į.
FEB 2 6 2002	5						TEU	HCFATER	۰	_
漫 . 8				ОТ	HER PRIOR ART N	ON PATENT LITERATUR	E DOCUMENTS		600/	P90
PRADEMINANT PRADEMINANT	Examiner Initials*	Cite No. ¹			nagazine, journal, serial, syn	LLETTERS), title of the article (with the articl	e(s), volume-issue numl		T ²	
									_	ł
		\square							\top	İ
		$\vdash \vdash$							+	ł

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.